{"id":814396,"date":"2025-02-18T16:07:04","date_gmt":"2025-02-18T21:07:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-reports-full-year-2024-record-revenue-of-1-015-billion-and-exceeds-its-financial-guidance-for-royalty-revenue-adjusted-ebitda-and-non-gaap-diluted-eps\/"},"modified":"2025-02-18T16:07:04","modified_gmt":"2025-02-18T21:07:04","slug":"halozyme-reports-full-year-2024-record-revenue-of-1-015-billion-and-exceeds-its-financial-guidance-for-royalty-revenue-adjusted-ebitda-and-non-gaap-diluted-eps","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-reports-full-year-2024-record-revenue-of-1-015-billion-and-exceeds-its-financial-guidance-for-royalty-revenue-adjusted-ebitda-and-non-gaap-diluted-eps\/","title":{"rendered":"HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Fourth Quarter Total Revenue Increased 30% YOY to $298 million<\/span> and Royalty Revenue Increased 40% YOY to $170 million<\/span><\/i>\n <\/p>\n

\n Fourth Quarter Net Income Increased 60% YOY to $137 million<\/span>; Adjusted EBITDA Increased 61% YOY to $196 million<\/span>; GAAP EPS Increased 63% YOY to $1.06<\/span>; non-GAAP EPS Increased 54% YOY to $1.26<\/span>1<\/sup><\/i>\n <\/p>\n

\n Record Full Year 2024 Total Revenue Increased 22% YOY to $1,015 million<\/span> and Record Royalty Revenue Exceeded Guidance Increasing 27% YOY to $571 million<\/span><\/i>\n <\/p>\n

\n Full Year 2024 Net Income Increased 58% YOY to $444 million<\/span>; GAAP EPS Increased 63% YOY to $3.43<\/span>; Adjusted EBITDA Increased 48% YOY to $632 million<\/span> and non-GAAP EPS Increased 53% YOY to $4.23<\/span><\/i>
\n
\n 1<\/sup>
\n <\/i>
\n , Both Exceeding Guidance\u00a0<\/i>\n <\/p>\n

\n Reiterating 2025 Financial Guidance Ranges for Total Revenue of $1,150<\/span> – 1,225 million, Representing YOY Growth of 13% – 21%, Adjusted EBITDA of $755<\/span> – $805 million<\/span>, Representing YOY Growth of 19% – 27% and non-GAAP Diluted EPS of $4.95<\/span> – $5.35<\/span>, Representing YOY Growth of 17% – 26%1<\/sup><\/i>\n <\/p>\n

\n
\n SAN DIEGO<\/span>
\n <\/span>, Feb. 18, 2025<\/span><\/span> \/PRNewswire\/ —\u00a0Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024<\/span>, provided an update on its recent corporate activities and reiterated its 2025 financial guidance.<\/p>\n

“I am excited to announce that the significant growth we achieved throughout the year culminated in two important milestones for the Company: achievement of more than $1 billion<\/span> in total revenue and reaching a cumulative one million patients with our ENHANZE drug delivery technology. Our 2024 royalty revenue exceeded guidance driven by continued strong growth of DARZALEX SC and Phesgo, with modest initial contribution from VYVGART Hytrulo resulting from growing adoption and use primarily from its first indication for generalized myasthenia gravis. These three products will continue to drive our 2025 royalty revenues, with VYVGART Hytrulo becoming the largest dollar growth contributor in 2025,” said Dr. Helen Torley<\/span>, president and chief executive officer of Halozyme.<\/p>\n

“I am also pleased that we achieved four additional, significant ENHANZE regulatory product and indication approvals in the U.S. and EU in 2024 for VYVGART Hytrulo for CIDP, Tecentriq Hybreza, Ocrevus Zunovo and Opdivo Qvantiq, positioning Halozyme for strong continued growth, post 2025, once coverage reimbursement and access are fully established,” said Dr. Torley.<\/p>\n

“Our leadership position in rapid subcutaneous drug delivery and long-term growth was further fortified with five new ENHANZE nominations from argenx and ViiV and an extension of our ENHANZE patent in Europe<\/span> out to 2029, with a similar patent submitted in the U.S. Our 2025 guidance reflects our confidence in continuing robust total revenue, royalty revenue, adjusted EBITDA and non-GAAP EPS growth,” Dr. Torley concluded.<\/p>\n

\n Fourth Quarter and Recent Corporate Highlights:<\/b>\n <\/p>\n